Well, that didn't take long. Just days after announcing its first shipment of 1.5 million doses of Fluvirin flu vaccine, Chiron
Chiron blamed the reduction on the length of time it took to remediate its Liverpool (England) factory. Contamination discovered there last year limited the amount of vaccine it could produce in eggs. Back in April, Chiron said it could produce as many as 30 million doses; in June, it cut that number to 26 million. Shouldn't the company have known its true capacity before flu season began? In any case, Chiron's net income is expected to fall below the company's July low-end estimates of $0.86 a share.
In light of the setback, Novartis
Once again, Chiron's stumble presents an opportunity for its competitors. Sanofi-Aventis
Both Henry Schein
With its earnings release due next week, perhaps Chiron was simply preparing investors for a jolt that no vaccine can cure.
Get a dose of related Foolishness here: